Travere Therapeutics Inc

TVTX

Company Profile

  • Business description

    Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

  • Contact

    3611 Valley Centre Drive
    Suite 300
    San DiegoCA92130
    USA

    T: +1 888 969-7879

    E: [email protected]

    https://www.travere.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    497

Stocks News & Analysis

stocks

ASX miner weathers the storm with strong commodity prices

Lower volumes due cyclone activity but revenues hold steady.
stocks

Eli Lilly earnings: Mounjaro/Zepbound’s massive volume growth more than counters price pressure

We’ve raised our fair value estimate of Lilly stock.
stocks

OpenAI missed multiple revenue targets - here’s why it likely won’t IPO this year

Plus, whichever AI company IPOs first defines what “good” looks like.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,954.7021.20-0.24%
CAC 408,114.840.000.00%
DAX 4024,292.38337.821.41%
Dow JONES (US)49,499.27152.87-0.31%
FTSE 10010,363.9314.89-0.14%
HKSE25,776.53335.31-1.28%
NASDAQ25,114.44222.130.89%
Nikkei 22559,513.12228.200.38%
NZX 50 Index13,039.20135.891.05%
S&P 5007,230.1221.110.29%
S&P/ASX 2008,729.8021.20-0.24%
SSE Composite Index4,112.164.650.11%

Market Movers